In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study
Kostas Triantaphyllopoulos, PhDLeigh Madden, MDInma Rioja, PhDDavid Essex, MDJacky Buckton, PhDRajneesh Malhotra, PhDKeith Ray, PhDMichael Binks, PhDEwa M. Paleolog, PhD
Please address correspondence and reprints requests to:
Dr Kostas Triantaphyllopoulos, Faculty of Medicine, Imperial College London
National Heart and Lung Institute, Guy Scadding Building,Dovehouse Street,
London SW3 6LY, United Kingdom.E-mail:
k.triantaphyllopoulos@imperial.ac.ukReceived on May 13, 2009; accepted in revised form on October 29, 2009.© Copyright EXPERIMENTALCLINICAL RHEUMATOLOGY AND
2010.Abbreviations:
A-SAA: ATP: acute phase serum amyloid A; CIA: adenosine triphosphate; CFA: collagen-induced arthritis; ELISA: complete Freund’s adjuvant; enzyme-linked immunosorbent BLC1/CXCL13: B lymphocyte assay;
FCS: chemoattractant; HUVEC: foetal calf serum hIL: cells; uman umbilical vein endothelial LPS: interleukin; MAPK: lipopolysaccharide;
MAPKAP 2: mitogen-activated protein mitogen-activated protein kinase; MCP: kinase-activated protein kinase 2; monocyte chemoattractant MKP: protein;
MSK: MAPK phosphatise;
mitogen- and stress-activated RA: kinase; STAT: rheumatoid arthritis;
signal transducers and activators TNF-VEGF: α: of transcription;
tumour necrosis factor α; vascular endothelial growth factorCon ict of interest: This work was sponsored by GlaxoSmithKline (GSK) through the Alternative Discovery
Initiative. Drs Rioja, Buckton and Binks are employees of GSK; Dr Malhotra is a former employee of GSB; Dr Ray is a former employee of GSB and declares a competing nancial interest; the other authors declare no competing interests.
Introduction
The host immune system is highly regu-lated in terms of space and time. Loss of this control can lead to a number of diseases, tis diseases, (RA), including chronic rheumatoid arthri-and systemic disorder, characterised by pro-septic neurodegenerative in ammatory shock. RA is a chronic disorders bowel and gressive destruction of articular cartilage and bone, and thought to be triggered by a combination of genetic susceptibility and exposure to environmental factors.The p38 mitogen-activated protein ki-nase (MAPK) pathway is involved in a number of cellular processes critical to the activation and in ltration of leukocytes, development of RA, for example, as well as production of in ammatory cytokines. kinase p38 is a serine/threonine kinase, Mitogen-activated protein and been characterised, namely p38four p38 MAPK isoforms p38α p38have β, no-acid γ, and p38δ, which share a 12-ami-TGY motif located at amino acid posi-activation loop containing a tions 180-182, which are subsequently phosphorylated at the residues Thr180 and Tyr182 leading to p38 MAPK ac-tivation. p38 MAPK occurs by tyrosine-speci c The inactivation process of MAPK tyrosine phosphatases 1 studied isoform is p38(MKP1) and (MKP) such as (1). threonine The most phosphatase was synthesis shown to be involved α MAPK, which extensively in (TNF-transcriptional α) and interleukin (IL)-1of tumour necrosis factor the bio-α More volved in the regulation of pro-in am-importantly, and translational β at the p38 MAPK is level. in-matory mediators to initiate leukocyte recruitment tokine gene expression (2).
and activation, and cy-Many p38 MAPK inhibitors have dem-onstrated ef cacy in animal models of arthritic inhibitors have been in phase II clini-disease and at least two p38 cal trials for RA; however many have failed due to unacceptable side-effects. In the the present study, we GW856553X MAPK inhibitory investigated compounds analogue GSK678361 for and its close structural cacy in mouse models of arthritis, and in vivo ef -in to in determine vitro validation whether studies, the compounds
in order 177
modulate genesis. The aims of this study were to in ammation and/or angio-investigate turally differences in these struc-ing similar compounds, by study-and the ef cacy and dose responses tions or side-effects in the animal set-most importantly adverse reac-ting. evaluated for the treatment of chronic GW856553X is currently being obstructive man phase II clinical trials. We deter-pulmonary disease in hu-mined the effect of single daily dosing with GW856553X in acute and chronic collagen-induced chronic model of arthritis we have used arthritis (CIA). The closely mimics RA and hence is a poten-tially good predictor of clinical ef cacy (3, 4). The inhibition by GW856553X of acute CIA was mirrored by disease amelioration was in chronic CIA, which tor, namely GSK678361. Furthermore, con rmed using another inhibi-when GSK678361 was administered to mice 2 weeks after onset of symptoms of able chronic CIA, joint to this compound was nism in ammation. abolish symptoms and reverse that GW856553X inhibited human en-of action studies Moreover, demonstrated mecha-dothelial cell angiogenesis reduced in vitro, and production pro-in ammatory These data suggest that p38 MAPK in-(IL-6, IL-8 and MCP-1). cytokine hibitors may have therapeutic potential for future use in RA.
Materials and methodsMaterials
GW856553X structurally MAPK, related and inhibitors GSK678361 of p38are αexhibit with a which also inhibit p38β but enzymes respect high degree of selectivity measuring and to receptors other protein (5). In kinases, assays and human GSK678361 the effects of GW856553 cells, the compounds were found to in-peripheral blood on LPS-stimulated mononuclear hibit tory cytokines TNF-production of the pro-in amma-31nM and 12nM respectively, data not α (IC50 values of shown). Similar potencies were found against IL-1Human recombinant vascular endothe-β, IL-6 and IL-8.
lial growth factor (VEGF) and human recombinant Systems, Abingdon, TNF-α were UK, and from human
R&D
p38 inhibition and not MK2 inhibition enhances ...efficacy in in vitro and in vivo inflammatory ... Novel inhibitor of p38 MAP kinase as an anti...
(2013) In Vitro and In Vivo Experimental Models...Efficacy of Antineoplastic Drugs on Urinary Bladder...inhibition are the oldest and most commonly used ...
The potent anti-leukemia efficacy of Icaritin in murine model demonstrated ... Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a...
of 4T1 breast cancer in vitro and in vivo. ...In vivo growth-inhibition of Sarcoma 180 by ...Chemopreventive efficacy of curcumin and piperine ...
namely stimulation of osteoblastic cell proliferation and inhibition of ...In summary, the present study clearly demonstrates the in vivo efficacy of ...
Experimental models of elevated Pgc in vivo ...In vitro mechanical stimulation therefore represents ...of p38 MAP kinase and subsequent inhibition by ...
Target validation Seattle/Chicago: Structure ...(in vitro systems) Biochemical (kinase, protease,...Inhibition Slide 20 deCODE Capabilities: In Vivo ...
In vitro models (enzyme inhibition, receptor ...and in silico) Bottleneck: Target validation, “... www.kubinyi.de MAP Kinase Pathways Kinases www....
[1] Target: p38 MAPK in vitro: In SHR-SPs receiving a salt-fat diet...Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, ...
Efficacy of a Tyrosine... 暂无评价 9页 免费 ...in vitro screening for tyrosine kinase inhibitors ...Also, there is substantial in vivo inhibition of...
热门文档